TAO Synergies Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $772.5KTTM through 30 Jun 2026
Net Income -$16.7MTTM through 30 Jun 2026
Free Cash Flow -$6.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 95.5% |
| Operating Margin | -343.4% |
| Net Margin | -2,155.5% |
Returns
-130.6%ROE
-78.9%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio19.99x
Net Debt-$3.6Mnet cash position
Cash & Equivalents$2.4M
Quality Metrics
Altman Z-Score-3.08
Piotroski F-Score1 / 9
FCF Margin-803.0%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $299.1K
Diluted EPS-$1.65TTMFY2025: $-8.71
Dividend
No dividend
Capital Allocation
R&D Spend$173.3K
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Digital Asset Treasury & Staking | $388.8K | View detailsThe company continues to execute its long-only TAO accumulation and staking strategy, utilizing third-party validators tao5 and Yuma Validator, LLC to generate yield. | |
| Biopharmaceuticals | $0 | View detailsThe company is evaluating its strategy for Bryostatin-1, its novel drug candidate targeting the activation of Protein Kinase C Epsilon (PKC̅) for Alzheimer's disease and other neurodegenerative conditions. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.